跳转至内容
Merck
CN

903H-0

MART-1 (M2-7C10) + Tyrosinase (T311) Mouse Monoclonal Antibody

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
M2-7C10 + T311, monoclonal
Application:
Citations:
8
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

mouse

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

M2-7C10 + T311, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

bottle of 1.0 mL predilute (903H-07), bottle of 7.0 mL predilute (903H-08)

isotype

IgG2a, IgG2bκ

shipped in

wet ice

storage temp.

2-8°C

Quality Level

Gene Information

human ... MLANA(2315)

General description

MART-1 (also known as Melan A) is a melanocyte differentiation antigen. It is present in melanocytes of normal skin and retina, nevi and in more than 85% of melanomas. Tyrosinase is an enzyme integral in the process of melanin synthesis, and found in 85% to 90% of malignant melanomas. Given these statistics, this cocktail is ideally suited to detection of melanomas and melanocytic lesions.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Analysis Note


IVD

IVD

IVD

RUO

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

未找到合适的产品?  

试试我们的产品选型工具.

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Deepali Gupta et al.
The American journal of surgical pathology, 26(11), 1450-1457 (2002-11-01)
Malignant melanomas of the vagina are rare tumors. In this study we present the clinicopathologic features and immunohistochemical analysis of 26 such cases seen in our institution over a period of 30 years. The patients' age ranged from 38 to
Guy Orchard
British journal of biomedical science, 59(4), 196-202 (2003-02-08)
Incidence of malignant melanoma (MM) is rising rapidly throughout the Western world, and the number of melanocytic lesions removed for histological assessment has increased. MM can present with a myriad of histological appearances that make diagnosis problematic, particularly when dealing
T J de Vries et al.
The Journal of pathology, 193(1), 13-20 (2001-02-13)
With the recent availability of novel antibodies against melanoma antigens tyrosinase and MART-1, it is important to validate their usefulness in pathology practice and in screening patients for immunotherapy treatment. In the present study conducted by the Melanoma Cooperative Group
M L Prasad et al.
The American journal of surgical pathology, 25(6), 782-787 (2001-06-08)
Malignant melanomas of the oral and sinonasal mucosa are rare tumors. Amelanotic variants can, on occasion, be difficult to recognize by routine light microscopy. Immunohistochemical studies may be needed for a final diagnosis. A number of new monoclonal antibodies to
Vinod B Shidham et al.
BMC cancer, 3, 15-15 (2003-05-09)
MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100 protein and HMB-45. To achieve higher sensitivity, some studies recommend evaluation of three sections, each at intervals

商品

IHC antibodies enhance dermatopathology beyond H&E stained slides, improving techniques and applications for dermatological research.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持